Ji Luo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/30255/publications.pdf

Version: 2024-02-01

65 papers	13,985 citations	87723 38 h-index	110170 64 g-index
66 all docs	66 docs citations	66 times ranked	22984 citing authors

#	Article	IF	Citations
1	The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Reviews Genetics, 2006, 7, 606-619.	7.7	2,833
2	Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction. Cell, 2009, 136, 823-837.	13.5	1,576
3	Drugging the undruggable RAS: Mission Possible?. Nature Reviews Drug Discovery, 2014, 13, 828-851.	21.5	1,484
4	Targeting the PI3K-Akt pathway in human cancer. Cancer Cell, 2003, 4, 257-262.	7.7	1,230
5	A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene. Cell, 2009, 137, 835-848.	13.5	912
6	Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5322-5327.	3.3	728
7	NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. Nature, 2016, 531, 253-257.	13.7	552
8	Breast Cancerâ€“Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells. Cancer Research, 2005, 65, 10992-11000.	0.4	456
9	Cancer Proliferation Gene Discovery Through Functional Genomics. Science, 2008, 319, 620-624.	6.0	365
10	Non-Oncogene Addiction and the Stress Phenotype of Cancer Cells. Cell, 2007, 130, 986-988.	13.5	320
11	Acute effects of leptin require PI3K signaling in hypothalamic proopiomelanocortin neurons in mice. Journal of Clinical Investigation, 2008, 118, 1796-1805.	3.9	293
12	Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKCÎ»/Î¶. Cell Metabolism, 2006, 3, 343-353.	7.2	249
13	Class IA Phosphoinositide 3-Kinase Regulates Heart Size and Physiological Cardiac Hypertrophy. Molecular and Cellular Biology, 2005, 25, 9491-9502.	1.1	187
14	Recurrent Hemizygous Deletions in Cancers May Optimize Proliferative Potential. Science, 2012, 337, 104-109.	6.0	172
15	Tau Positron-Emission Tomography in Former National Football League Players. New England Journal of Medicine, 2019, 380, 1716-1725.	13.9	165
16	Phosphoinositide 3-kinase regulatory subunit p85Â suppresses insulin action via positive regulation of PTEN. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 12093-12097.	3.3	149
17	The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. Journal of Cell Biology, 2005, 170, 455-464.	2.3	146
18	The Phosphoinositide 3-Kinase Regulatory Subunit p85Î± Can Exert Tumor Suppressor Properties through Negative Regulation of Growth Factor Signaling. Cancer Research, 2010, 70, 5305-5315.	0.4	140

#	Article	IF	Citations
19	Class IA Phosphatidylinositol 3-Kinase in Pancreatic Î² Cells Controls Insulin Secretion by Multiple Mechanisms. Cell Metabolism, 2010, 12, 619-632.	7.2	101
20	Differential Effector Engagement by Oncogenic KRAS. Cell Reports, 2018, 22, 1889-1902.	2.9	101
21	MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 4508-4517.	3.3	97
22	Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia. Cell Metabolism, 2006, 3, 355-366.	7.2	96
23	Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9739-9744.	3.3	96
24	KRAS mutation in pancreatic cancer. Seminars in Oncology, 2021, 48, 10-18.	0.8	95
25	Development of siRNA Payloads to Target KRAS-Mutant Cancer. Cancer Discovery, 2014, 4, 1182-1197.	7.7	93
26	Then Negative Regulation of Phosphoinositide 3-Kinase Signaling by p85 and Its Implication in Cancer. Cell Cycle, 2005, 4, 1309-1312.	1.3	92
27	Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development. Cell Death and Disease, 2018, 9, 620.	2.7	90
28	LAMC2 enhances the metastatic potential of lung adenocarcinoma. Cell Death and Differentiation, 2015, 22, 1341-1352.	5.0	89
29	Phosphatidyl Inositol 3-Kinase Signaling in Hypothalamic Proopiomelanocortin Neurons Contributes to the Regulation of Glucose Homeostasis. Endocrinology, 2009, 150, 4874-4882.	1.4	82
30	Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders. Chemical Science, 2020, 11, 3474-3486.	3.7	77
31	The p85Î± Regulatory Subunit of Phosphoinositide 3-Kinase Potentiates c-Jun N-Terminal Kinase-Mediated Insulin Resistance. Molecular and Cellular Biology, 2007, 27, 2830-2840.	1.1	74
32	Sjogren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16882-16887.	3.3	68
33	High mesothelin expression in advanced lung adenocarcinoma is associated withKRASmutations and a poor prognosis. Oncotarget, 2015, 6, 11694-11703.	0.8	66
34	CRISPR/Cas9-mediated gene knockout is insensitive to target copy number but is dependent on guide RNA potency and Cas9/sgRNA threshold expression level. Nucleic Acids Research, 2017, 45, 12039-12053.	6.5	64
35	Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1724-33.	3.3	57
36	Global Inhibition with Specific Activation: How p53 and MYC Redistribute the Transcriptome in the DNA Double-Strand Break Response. Molecular Cell, 2017, 67, 1013-1025.e9.	4.5	55

#	Article	IF	Citations
37	T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. Blood, 2007, 109, 2894-2902.	0.6	54
38	Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 10238-10243.	3.3	43
39	Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation. Science Signaling, 2018, 11, .	1.6	38
40	Cancer's sweet tooth for serine. Breast Cancer Research, 2011, 13, 317.	2.2	29
41	Genetic interrogation of replicative senescence uncovers a dual role for USP28 in coordinating the p53 and GATA4 branches of the senescence program. Genes and Development, 2017, 31, 1933-1938.	2.7	28
42	The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status. Nature Communications, 2019, 10, 5428.	5.8	28
43	Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma. Scientific Reports, 2015, 5, 9357.	1.6	26
44	Genomeâ€wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. Molecular Systems Biology, 2019, 15, e8323.	3.2	25
45	A primer on using pooled shRNA libraries for functional genomic screens. Acta Biochimica Et Biophysica Sinica, 2012, 44, 103-112.	0.9	24
46	A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing. Nature Communications, 2021, 12, 6512.	5.8	24
47	Selective targeting of KRAS-Mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-Mutant cells. Oncotarget, 2014, 5, 7635-7650.	0.8	21
48	Wortmannin-C20 Conjugates Generate Wortmannin. Journal of Medicinal Chemistry, 2006, 49, 740-747.	2.9	20
49	A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. Oncotarget, 2016, 7, 10696-10709.	0.8	19
50	Genome-Wide RNAi Screen Identifies PMPCB as a Therapeutic Vulnerability in EpCAM+ Hepatocellular Carcinoma. Cancer Research, 2019, 79, 2379-2391.	0.4	19
51	A High-Throughput Assay for Small Molecule Destabilizers of the KRAS Oncoprotein. PLoS ONE, 2014, 9, e103836.	1.1	18
52	Synthesis and Activity of C11-Modified Wortmannin Probes for PI3 Kinase. Bioconjugate Chemistry, 2005, 16, 669-675.	1.8	17
53	Metabolic supervision by PPIP5K, an inositol pyrophosphate kinase/phosphatase, controls proliferation of the HCT116 tumor cell line. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	16
54	Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation. Marine Drugs, 2015, 13, 3625-3639.	2.2	15

#	Article	IF	Citations
55	Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1. Oncogene, 2021, 40, 6759-6771.	2.6	13
56	Male-Biased Effects of Gonadotropin-Releasing Hormone Neuron-Specific Deletion of the Phosphoinositide 3-Kinase Regulatory Subunit p85Î± on the Reproductive Axis. Endocrinology, 2009, 150, 4203-4212.	1.4	11
57	Flexible CRISPR library construction using parallel oligonucleotide retrieval. Nucleic Acids Research, 2017, 45, e101-e101.	6.5	11
58	Multiplexed CRISPR/Cas9 gene knockout with simple crRNA:tracrRNA co-transfection. Cell and Bioscience, 2019, 9, 41.	2.1	11
59	One-step immortalization of primary human airway epithelial cells capable of oncogenic transformation. Cell and Bioscience, 2016, 6, 57.	2.1	9
60	Synthetic Lethal Genetic Screens in Ras Mutant Cancers. The Enzymes, 2013, 34 Pt. B, 201-219.	0.7	7
61	SUMO wrestling with Ras. Small GTPases, 2016, 7, 39-46.	0.7	5
62	Host CLIC4 expression in the tumor microenvironment is essential for breast cancer metastatic competence. PLoS Genetics, 2022, 18, e1010271.	1.5	2
63	Using Pooled miR30-shRNA Library for Cancer Lethal and Synthetic Lethal Screens. Methods in Molecular Biology, 2014, 1176, 45-58.	0.4	1
64	Phosphoinositide biology â€“ messages from lipids. Nature Cell Biology, 2000, 2, E190-E190.	4.6	0
65	The Achilles Heel of Malignant Rhabdoid Tumors. Cancer Research, 2019, 79, 2808-2809.	0.4	0